Automated Insulin Dosing for T2D Using MDI-to-CSII Conversion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional AID systems designed for Type 1 diabetes (T1D) patients are inadequate for Type 2 diabetes (T2D) patients due to differences in glucose metabolism and insulin kinetics, necessitating a tailored system for efficient and accurate insulin delivery without manual estimations.
Innovation Solution
An insulin infusion process that converts multiple daily injection (MDI) therapy information for T2D patients into continuous subcutaneous insulin infusion (CSII) information, using safety constraints and algorithms to deliver insulin based on mean blood glucose differences and target glucose levels, incorporating finger-stick measurements when necessary.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If conventional AID systems designed for T1D patients are used, then automated insulin delivery is achieved, but the system is inadequate for T2D patients due to differences in glucose metabolism and insulin kinetics
Solution Approach 1:
The patent modifies the AID system parameters specifically for T2D patients by adjusting insulin delivery algorithms, glucose target ranges, and insulin sensitivity factors to account for differences in glucose metabolism and insulin kinetics between T1D and T2D patients, thereby achieving both adaptability and reliability
2Ease of operation
If manual blood glucose measurements and needle injections are used for T2D patients, then treatment is simple to implement, but the burden of manual insulin delivery is high and accuracy is reduced
Solution Approach 1:
The AID system enables automated self-adjustment of insulin delivery based on continuous glucose monitoring data, eliminating the need for manual calculations and injections by the patient, thereby reducing the time burden while maintaining ease of use through automatic operation
3Device complexity
If conventional AID systems are used without modification, then device complexity is low, but measurement precision of blood glucose levels is insufficient for accurate insulin dosing
Solution Approach 1:
The patent replaces manual finger-stick measurement methods with continuous glucose monitoring (CGM) technology that automatically measures glucose levels in interstitial fluid, providing continuous precise data to the AID system without adding significant operational complexity
Data Source
AI summary
Methods and apparatuses for performing an insulin infusion process are described. For example, an apparatus may include at least one memory and logic coupled to the at least one memory. The logic may operate to determine a basal parameter for a patient based on a type 2 diabetes (T2D) multiple daily injection (MDI) information of the patient, the basal parameter indicating a basal infusion rate, determine an additional insulin (Iadd) value based on a mean blood glucose difference (BGdiff) information associated with the patient, determine an insulin volume to infuse into the patient based on the basal parameter and Iadd, and administer the insulin volume to the patient. Other embodiments are described.